headquarters_3_web

Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

pharmafile | May 8, 2019 | News story | Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma 

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.

Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.

Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.

Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”

“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”  

The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.

Louis Goss

Related Content

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …

lilly_entrance_web

Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content